Again, about a month later, another approval was granted, this time for the KEYNOTE-811 regimen, which combines pembrolizumab with chemotherapy and trastuzumab for HER2+ GEJC and GC, showing an objective response rate of 74.4% for the triple combination vs. 51.9% for hormonal therapy plus chemotherapy, and complete response rates of 11.3% vs. 3.1%, respectively [70]. This evidence concerns the gene ERBB2 and gastric cancer.